| Methods |
2‐ to 3‐week screening/washout period; 4‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 95‐114 mm Hg; 12‐week double‐blind treatment |
| Participants |
Enalapril 20 mg: n=72(44 males,28 females); mean age=53.1(11.0) years; baseline supine SBP=153.8(13.8) mm Hg, DBP=100.4(4.2) mm Hg;
Placebo: n=76(49 males,27 females); mean age=55.6(9.6) years; baseline supine SBP=154.8(11.8) mm Hg, DBP=100.4(4.5) mm Hg |
| Interventions |
Enalapril 20 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported; endpoint BP and SD not reported; calculated SD of change from N and SE of change; change in BP data from Figures 1 and 2, p. 235; SE of change data from Table 2, p. 234; Jadad score=3; funding source= Boehringer Ingelheim Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
